Latest News

It's a battle between the world's most successful chipmaker and tech conglomerate.

If this satellite company delivers broadband directly to billions of smartphones, early investors could see big returns.

Discover the potential of Capital Power as a leading dividend stock on TSX for reliable returns and future growth.

These TSX stocks will likely deliver solid returns as they are benefiting from strong demand for their products, technology, and services.

Plug achieved some notable progress in 2025, and it's making me reconsider the beleaguered stock.

The social media giant is delivering exceptional top-line growth, but could a massive planned increase in capital expenditures derail the company's earnings momentum?

The tech giant is normally a much safer buy than it's been this year.

Archer's expenses are rising, and it may take years before the company generates meaningful revenue from its air taxi business.

This strategy can boost yield while reducing portfolio risk.

Oil whipsawed, with WTI briefly topping $119 before plunging toward the low $80s as Trump said the Iran war could end soon.

Turn $25,000 into monthly passive income! Discover how a single TSX ETF, a TFSA, and a DRIP can build a bulletproof portfolio that pays you cash every single month, tax-free...

It's about to join a stock index closely followed by small-cap stock hunters.

Investors have turned sharply bearish on GitLab recently.

Understanding these RMD rules can help you avoid making costly mistakes.

The fuel cell provider is benefiting from incredibly strong demand from technology companies.

Ross Stores recently posted some fantastic earnings numbers that blew past its own guidance.

Shares of Sweetgreen crashed nearly 80% last year.

The AI chipmaker has been investing heavily across the AI landscape. The broader market has taken notice.

High yields look scary until you separate “cash flow coverage” from “headline yield,” and these two TSX names show both sides.

Netflix investors are feeling the opposite of buyer's remorse.

Here are my three top picks to consider during this volatile market environment due to war-driven uncertainty.

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.